ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA…
Providence, Rhode Island, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company working to accelerate…
Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference…
BURNABY, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific…
Tomlinson et al. Bayesian methods: a potential path forward for sepsis trials. Critical Care (2023) 27:432TORONTO, Nov. 14, 2023 (GLOBE…
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the…
Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive…
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1 ATSN-101 has demonstrated clinically…
CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on…
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditionsParticipating investors include…